Debottlenecking R&D with Automated Powder Dispensing
contributed by Mettler Toledo |
The Enabling Technologies Consortium™ (ETC) - group of major pharmaceutical and biotechnology companies - has published a new study on powder dispensing with the aim of easing R&D bottlenecks, particularly in high-throughput experimentation.
In an effort to understand the relative merits and disadvantages of existing automated powder dispensing technologies, an independent evaluation was carried out by the ETC's High Throughput Experimentation (HTE) working group. This working group comprised of AstraZeneca (AZ), Bristol-Myers Squibb (BMS), GlaxoSmithKline (GSK), Merck & Co., and Pfizer. The study evaluated four commercially available automated powder dispensing platforms, including Quantos from METTLER TOLEDO, to assess their abilities to accurately weigh a wide range of different powder types into vials.
The results of this benchmarking study, entitled "Collaborative Evaluation of Commercially Available Automated Powder Dispensing Platforms for High Throughput Experimentation in Pharmaceutical Applications", were presented at Pittcon 2018  and will be published in OPRD .
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine